Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Advanced or Metastatic HER2+ Solid Tumors
NCT02593708Phase 1Terminated
- Start
- Nov 2015
- Primary completion
- Jan 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of neratinib in solid tumor (4 cohorts). Primary endpoints: Adverse Events up to 2 years and Maximum Tolerated Dose up to 2 years. Started Nov 2015; status: terminated.
02
Drugs
neratinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02593708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593708.